Fosribnicotinamide-d4

Fosribnicotinamide-d4 (β-Nicotinamide mononucleotide-d4) is the deuterium labeled Fosribnicotinamide. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].

Product Specifications

Product Name Alternative

β-Nicotinamide mononucleotide-d4; β-NM-d4; NMN-d4

UNSPSC

12352005

Target

Endogenous Metabolite; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Field of Research

Cancer; Neurological Disease

Purity

99.55

Solubility

H2O : 83.33 mg/mL (ultrasonic; warming)

Smiles

O[C@@H]1[C@H](O)[C@@H](COP(O)([O-])=O)O[C@H]1[N+]2=C([2H])C([2H])=C([2H])C(C(N)=O)=C2[2H]

Molecular Formula

C11H11D4N2O8P

Molecular Weight

338.24

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Poddar SK, et al. Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule. Biomolecules. 2019;9 (1) :34. Published 2019 Jan 21.|[3]Lv H, et al. NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion [published online ahead of print, 2020 Nov 3]. Cell Metab. 2020; S1550-4131 (20) 30554-4.|[4]Li J, et al. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proc Natl Acad Sci U S A. 2019;116 (39) :19626-19634.|[5]Yoshino J, et al Nicotinamide mononucleotide, a key NAD (+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14 (4) :528-536.